JAK2 and acquired polycythemia vera: The JAK2 mutation frequency was reported to be below 1% in the normal population, whereas it was 62.2% in CMD cases; 97.6% in PV cases; 54.5% in ET cases and 53.44% in PMF cases (9, 10).